Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)
This study is currently recruiting participants.
Verified September 2012
by GITR, Inc.
Study NCT01239134 Information provided by GITR, Inc.
First Received on November 9, 2010. Last Updated on September 20, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
More general conditions related to this trial
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Interventions listed in this trial
Sponsors listed in this trial
Cancer Research Institute, New York City
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers